Summit Therapeutics revenue and financials

SMMT · NASDAQ · USD

$17.31+0.23%+$0.04

Close · October 6, 2026

Annual revenue · 2022: $705K
  1. $2.3M2017
  2. $25.42M2018
  3. $57.09M2019
  4. $860K2020
  5. $1.81M2021
  6. $705K2022

Fiscal year ending in December. Sources and method on the page Methodology and sources.

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue0.00.00.00.00.0———————
Selling, general and administrative62.862.677.610336015.614.220.713.811.511.65.4
Research and development15813314713120851.351.437.730.830.924.815.3
Operating income-220-195-225-234-568-66.9-65.6-58.4-44.6-42.4-36.2-20.5
EBIT-220-195-225-234-568-66.9-65.6-58.4-44.6-42.4-36.2-20.5
EBITDA-220-195-225-234-568-66.8-65.6-58.4-44.6-42.4-36.2-20.5
Interest expense——0.00.00.00.00.02.53.13.12.92.7
Pre-tax income-216-189-219-232-566-62.9-61.2-56.3-60.4-43.5-36.6-21.3
Net income-216-189-219-232-566-62.9-61.2-56.3-60.4-43.5-36.6-21.3
Net income to common shareholders-216-189-219-232-566-62.9-61.2-56.3-60.4-43.5-36.6-21.3
Basic EPS-0.28-0.24-0.29-0.31-0.76-0.09-0.08-0.08-0.09-0.06-0.05-0.03
Diluted EPS-0.28-0.24-0.29-0.31-0.76-0.09-0.09-0.08-0.09-0.06-0.05-0.03
Average shares (basic)778775766743743738738727708702701698
Average shares (diluted)778775766743743738738727708702701698